A Nanovaccine Approach For The Treatment of Pancreatic Cancer By Multicomponent Immuno-Modulation: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in men and women and still fatal in over 90% of patients. It is characterised by its extremely aggressive nature where it is also responsible for the highest mortality rate compared to other major cancers, resulting in excess of 250,000 deaths worldwide per annum. Current state-of-art therapies for advanced PDAC including chemo- and/or radiotherapy, despite extensive efforts, have met with only limited success.
Surgery is only applicable for those with early stages of the disease, or to relieve symptoms, if the cancer is blocking the bile duct or the bowel. There are two major reasons for the resistance of PDAC to conventional therapy. Firstly, PDAC has a very defining hallmark, where an abundance of stromal content is present in the tumour microenvironment (TME) to form a physical and biochemical barrier. Secondly, during progression of the disease, the body's immune system is hijacked to support the proliferation of the cancer. New approaches, such as immunotherapy, are therefore needed where it has already shown promise in overcoming many aspects of this resistance. Immunotherapy has the potential to treat minimal residual disease after pancreatic resection (surgery) as well as for metastatic and non-resectable PDAC. Our objective for this project
is to bring together a multidisciplinary and intersectoral group to develop novel vaccine approaches, including use of multiple immunomodulating components.
Field of science
- /medical and health sciences/clinical medicine/surgery
- /medical and health sciences/clinical medicine/cancer/pancreatic cancer
- /medical and health sciences/basic medicine/immunology/immunotherapy
Call for proposal
See other projects for this call
Funding SchemeMSCA-ITN-ETN - European Training Networks